Llwytho...
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Resistance to targeted therapeutics is a key issue limiting the long-term utility of these medications in the management of molecularly selected subsets of cancer patients, including patients with non-small cell lung cancer harboring oncogenic alterations affecting EGFR, ALK and other genes. Bypass...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ann Transl Med |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AME Publishing Company
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5253284/ https://ncbi.nlm.nih.gov/pubmed/28164089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2016.12.09 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|